

## References

1. Diamandis M, White NMA, Yousef GM. Personalized medicine: marking a new epoch in cancer patient management. *Mol Cancer Res*. 2010;8(9):1175-1187.
2. King GT, Lieu CH, Messersmith WA. Frontline strategies for metastatic colorectal cancer: new sides to the story. *Am J Hematol Oncol*. 2016;12(10):4-11.
3. Vectibix® (panitumumab) prescribing information, Amgen.
4. Kim TW, Elme A, Kusic Z, et al. A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type *KRAS* or *RAS* metastatic colorectal cancer. *Br J Cancer*. 2016;115(10):1206-1214.
5. Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type *KRAS* exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. *Lancet Oncol*. 2014;15(6):569-579.
6. Kobayashi Y, Komatsu Y, Yuki S, et al. Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001study; J-STEPP. *Future Oncol*. 2015;11(4):617-627.